(Q53620186)

16 May 2018

title

Halofuginone prevents subglottic stenosis in a canine model. (English)

1 reference

16 May 2018

1 reference

Ron Eliashar

1

1 reference

16 May 2018

Meir Ochana

2

1 reference

16 May 2018

Bella Maly

3

1 reference

16 May 2018

Mark Pines

4

1 reference

16 May 2018

Jean-Yves Sichel

5

1 reference

16 May 2018

Arnon Nagler

6

1 reference

16 May 2018

publication date

1 May 2006

1 reference

16 May 2018

Annals of Otology Rhinology and Laryngology

number of pages

5

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

16 May 2018

volume

115

1 reference

16 May 2018

issue

5

1 reference

16 May 2018

page(s)

382-386

1 reference

16 May 2018

Halofuginone: a novel antifibrotic therapy

cites work

1 reference

https://api.crossref.org/works/10.1177%2F000348940611500511

Halofuginone: a potent inhibitor of critical steps in angiogenesis progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000348940611500511

Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000348940611500511

21 January 2018

Cutaneous wound healing

1 reference

https://api.crossref.org/works/10.1177%2F000348940611500511

Inhibition of subglottic stenosis with mitomycin-C in the canine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000348940611500511

Preservation of function and histologic appearance in the injured glottis with topical mitomycin-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000348940611500511

Mitomycin: effects on laryngeal and tracheal stenosis, benefits, and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000348940611500511

The role of mitomycin in the prevention and treatment of scar formation in the pediatric aerodigestive tract: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000348940611500511

Idiopathic subglottic stenosis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000348940611500511

Growth inhibition of prostate cancer xenografts by halofuginone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000348940611500511

Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000348940611500511

Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000348940611500511

Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000348940611500511

The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of esophageal strictures related to caustic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000348940611500511

10.1177/000348940611500511

21 January 2018

Identifiers

DOI

1 reference

16 May 2018

1 reference

16 May 2018